Physician profile
Terri Dunn
NPI 1760543300
$79,046.48
in general payments reported to CMS, 2019-2025
33 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,363 · 2021: $3,306 · 2022: $1,118 · 2023: $3,350 · 2024: $19K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $8,032 · Consulting Fee: $4,875 · Travel and Lodging: $1,295 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,702.64 |
| Food and Beverage | $8,032.36 |
| Consulting Fee | $4,875.00 |
| Travel and Lodging | $1,295.10 |
| Education | $229.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69,651.32 | 2019-2025 | |
| Abbvie INC. | $1,518.29 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Leo Pharma INC. | $1,184.69 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $709.04 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $676.44 | 2019-2025 | Tremfya |
| Incyte Corporation | $565.38 | 2021-2025 | Opzelura |
| Genzyme Corporation | $560.23 | 2019-2025 | |
| Biofrontera INC. | $468.96 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $447.96 | 2020-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $384.96 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $376.28 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $363.07 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $312.96 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $298.31 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $286.13 | 2019-2025 | Dupixent, Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $198.90 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Revance Therapeutics, INC. | $157.26 | 2024-2025 | Daxxify |
| Almirall LLC | $119.01 | 2019-2024 | Seysara, Klisyri |
| Sandoz INC. | $117.55 | 2019 | |
| Allergan, INC. | $112.64 | 2019-2022 | |
| Strata Skin Sciences, INC. | $105.04 | 2019-2025 | Xtrac |
| Mayne Pharma Commercial LLC | $90.46 | 2019-2020 | |
| Organon LLC | $71.42 | 2025 | Vtama |
| Genentech USA, INC. | $49.65 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $39.59 | 2019 | |
| Biocon Biologics INC | $28.39 | 2024 | Hulio |
| Novartis Pharmaceuticals Corporation | $27.74 | 2024 | |
| Ucb, INC. | $26.86 | 2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $23.40 | 2025 | Ycanth |
| Journey Medical Corporation | $19.69 | 2022 | |
| Epi Health, LLC | $18.79 | 2021 | |
| Dermira, INC. | $18.64 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $17.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.